By using MCF-7 breast cancer cells overexpressing a UBC9 dominant-negative mutant (UBC9-DN), or wild type UBC9 in a mouse xenograft model, it was shown that tumors expressing the UBC9 mutant exhibited reduced growth, whereas wild type UBC9 enhanced tumor growth [21]. This evidence concerns the gene UBE2I and neoplasm.